Synthesis and Antiproliferative Activity Evaluation of Aryl(Hetaryl)Cyclopentenone Analogs of Combretastatin A-4


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Somente assinantes

Resumo

A series of previously unreported di- and triaryl(hetaryl)cyclopentenone derivatives were prepared using a convenient synthetic method and screened preliminarily for antitumor activity in four human cell lines, i.e., T-cell leukemia (Jurkat), lung adenocarcinoma (A-549), colon cancer (HCT-116), and breast adenocarcinoma (MCF-7). The most cytotoxic of the tested compounds was 2-(3,4,5-trimethoxyphenyl)-3-(4-methoxyphenyl) cyclopent-2-en-1-one. However, it was inactive against lymphocytic leukemia P388 in mice despite its cytotoxicity in in vitro tests.

Sobre autores

V. Shirinyan

N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences

Autor responsável pela correspondência
Email: shir@ioc.ac.ru
Rússia, 47 Leninskii Prosp, Moscow, 119991

A. Markosyan

Scientific and Technological Center of Organic and Pharmaceutical Chemistry, National Academy of Sciences of Armenia

Email: shir@ioc.ac.ru
Armênia, 26 Azatutyan Pr., 0014, Yerevan, 375014

M. Baryshnikova

N. N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences

Email: shir@ioc.ac.ru
Rússia, 23 Kashirskoe Shosse, Moscow, 115478

L. Yaminova

D. I. Mendeleev University of Chemical Technology of Russia

Email: shir@ioc.ac.ru
Rússia, 9 Miusskaya Pl., Moscow, 125047

A. L’vov

N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences

Email: shir@ioc.ac.ru
Rússia, 47 Leninskii Prosp, Moscow, 119991

S. Gabrielyan

Scientific and Technological Center of Organic and Pharmaceutical Chemistry, National Academy of Sciences of Armenia

Email: shir@ioc.ac.ru
Armênia, 26 Azatutyan Pr., 0014, Yerevan, 375014


Declaração de direitos autorais © Springer Science+Business Media, LLC, part of Springer Nature, 2018

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies